Porklog

H.R. 9547

Veterans and Servicemembers PTSD Emerging Treatment Review Act of 2026

Updated Aug 4, 2026, 4:07 AM ET

Bipartisan Not enacted

2. Report on emerging treatment options for treatment-resistant post-traumatic stress disorder (continued)

(9) Any potential expanded access pathway or pilot activity involving an investigational Schedule I substance must be evaluated in accordance with applicable Federal law and regulations, including requirements administered by the Food and Drug Administration and the Drug Enforcement Administration, and applicable regulatory agencies should act in a timely manner to issue or update regulations, guidance, authorizations, and procedures necessary to enable lawful research and access for eligible patients, consistent with the Federal Right to Try Act, expanded access authorities, and the April 18, 2026, Executive Order titled Accelerating Medical Treatments for Serious Mental Illness, while maintaining appropriate safety, security, and diversion-control safeguards.

(10) Congress has a responsibility to ensure that the Department of Defense assesses whether emerging clinical research may offer future benefit for active-duty servicemembers, reserve component members, veterans, and transitioning servicemembers with treatment-resistant post-traumatic stress disorder.

(b) Report Not later than 180 days after the date of the enactment of this Act, the Assistant Secretary of Defense for Health Affairs shall submit to the congressional defense committees a report on the operational relevance, safety, dosing, and feasibility of data from the covered clinical trial as such data would apply to members of the Armed Forces, including such members transitioning to civilian life.

Comments

No comments yet.